Filtered By:
Condition: Heart Disease
Nutrition: Vitamin K

This page shows you your search results in order of relevance. This is page number 9.

Order by Relevance | Date

Total 157 results found since Jan 2013.

The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V-Special Situations.
Abstract Non-vitamin K antagonist oral anticoagulants (NOACs) include dabigatran, which inhibits thrombin, and apixaban, betrixaban, edoxaban and rivaroxaban, which inhibit factor Xa. In large clinical trials comparing the NOACs with the vitamin K antagonist (VKA) warfarin, dabigatran, apixaban, rivaroxaban and edoxaban were at least as effective for stroke prevention in atrial fibrillation and for treatment of venous thromboembolism, but were associated with less intracranial bleeding. In addition, the NOACs are more convenient to administer than VKAs because they can be given in fixed doses without routine coagu...
Source: Thrombosis and Haemostasis - January 1, 2019 Category: Hematology Authors: De Caterina R, Ageno W, Agnelli G, Chan NC, Diener HC, Hylek E, Raskob GE, Siegal DM, Verheugt FWA, Lip GYH, Weitz JI Tags: Thromb Haemost Source Type: research

Oral Anticoagulation.
CONCLUSION: The evidence base for anticoagulation over a time frame of several years is inadequate at present, and direct comparative data for the different types of NOAC are not yet available. PMID: 30602410 [PubMed - in process]
Source: Deutsches Arzteblatt International - January 5, 2019 Category: General Medicine Tags: Dtsch Arztebl Int Source Type: research

Atrial Fibrillation in Rheumatic Heart Disease
AbstractPurpose of reviewAtrial fibrillation is the commonest sustained arrhythmia in rheumatic heart disease and is associated with significant morbidity and mortality. In this review, we discuss its epidemiology, natural course and management with special emphasis on recent developments in understanding and treatment of atrial fibrillation in rheumatic heart disease.Recent findingsUse of direct oral anticoagulants appears promising, especially in developing countries where regular coagulation monitoring is a challenge. Also, restoration and maintenance of sinus rhythm in rheumatic atrial fibrillation appear feasible and ...
Source: Current Treatment Options in Cardiovascular Medicine - October 10, 2020 Category: Cardiology Source Type: research

Use of Direct Oral Anticoagulants in the Treatment of Left Ventricular Thrombus: Systematic Review of Current Literature
Conclusions: The use of DOACs is a reasonable alternative to vitamin-K antagonists in the management of LVT.
Source: American Journal of Therapeutics - November 1, 2020 Category: Drugs & Pharmacology Tags: Systematic Review and Clinical Guidelines Source Type: research

Peak plasma rivaroxaban levels in patients weighing 120  kg or greater
Direct oral anticoagulants (DOACs) have become the drug of choice, increasingly replacing traditional vitamin K antagonists (VKA) for stroke prevention in atrial fibrillation (AF) and in the treatment of venous thromboembolism (VTE) due to their advantages of fixed dosing and no requirement for drug monitoring. Furthermore, their use is expanding into the ischemic heart disease population [1]. However, there is ongoing concern regarding their use in those weighing ≥120 kg or who have a body mass index (BMI) ≥ 40 due to limited representation of this patient group in the phase 3 DOAC trials [2,3].
Source: Thrombosis Research - February 17, 2021 Category: Hematology Authors: Jameel Abdulrehman, Rita Selby, Raed A. Joundi, Erik Yeo Tags: Letter to the Editors-in-Chief Source Type: research

Peak plasma rivaroxaban levels in patients weighing 120  kg or greater
Direct oral anticoagulants (DOACs) have become the drug of choice, increasingly replacing traditional vitamin K antagonists (VKA) for stroke prevention in atrial fibrillation (AF) and in the treatment of venous thromboembolism (VTE) due to their advantages of fixed dosing and no requirement for drug monitoring. Furthermore, their use is expanding into the ischemic heart disease population [1]. However, there is ongoing concern regarding their use in those weighing ≥120 kg or who have a body mass index (BMI) ≥ 40 due to limited representation of this patient group in the phase 3 DOAC trials [2,3].
Source: Thrombosis Research - February 17, 2021 Category: Hematology Authors: Jameel Abdulrehman, Rita Selby, Raed A. Joundi, Erik Yeo Tags: Letter to the Editors-in-Chief Source Type: research

Non-Vitamin K Antagonists versus Warfarin in Patients with Atrial Fibrillation and Bioprosthetic Valves: a Systematic Review and Meta-Analysis
Patients with bioprosthetic heart valves and valve repair with concomitant atrial fibrillation are at an increased risk of thromboembolic events.1-5 Until recently, there was a paucity of randomized data to guide the optimal anticoagulation strategy in this patient population. In a prior meta-analysis of 4 randomized studies in patients with atrial fibrillation and valvular heart disease, excluding significant mitral stenosis and mechanical valves, there was a significant reduction in the risk of stroke or systemic embolism with non-vitamin K antagonist oral anticoagulants (NOACs) vs.
Source: The American Journal of Medicine - October 7, 2021 Category: General Medicine Authors: Rhanderson Cardoso, Caique M.P. Ternes, Gustavo B. Justino, Amanda Fernandes, Ana Vitoria Rocha, Leonardo Knijnik, Andre d'Avila, Renato D. Lopes Tags: Clinical Research Study Source Type: research

Maternal and neonatal complications in women with congenital heart disease: a nationwide analysis
ConclusionsThis population-based study illustrates a reassuringly low maternal mortality rate in a highly developed healthcare system. Nevertheless, maternal morbidity and neonatal morbidity/mortality were significantly increased in women with ACHD and their offspring compared to non-ACHD controls highlighting the need of specialized care and pre-pregnancy counselling.
Source: European Heart Journal - October 12, 2021 Category: Cardiology Source Type: research

Antiplatelet agents and anticoagulants for hypertension
CONCLUSIONS: There is no evidence that antiplatelet therapy modifies mortality in patients with elevated BP for primary prevention. ASA reduced the risk of cardiovascular events and increased the risk of major bleeding events. Antiplatelet therapy with ASA probably reduces the risk of non-fatal and all cardiovascular events when compared to clopidogrel. Clopidogrel increases the risk of major bleeding events compared to ASA in patients with elevated BP for secondary prevention. There is no evidence that warfarin modifies mortality in patients with elevated BP for secondary prevention. The benefits and harms of the newer dr...
Source: Cochrane Database of Systematic Reviews - July 28, 2022 Category: General Medicine Authors: Eduard Shantsila Monika Kozie ł-Siołkowska Gregory Yh Lip Source Type: research

Daily Multivitamins Linked to Improved Cognition in Older People
Taking a daily multivitamin may improve cognitive function in older people, astudy inAlzheimer ’s& Dementia has found. Taking a cocoa supplement, however, does not appear to slow cognitive decline.“There is an urgent need to identify effective strategies to preserve cognitive function to mitigate the heavy societal burden associated with Alzheimer’s disease and related dementia, which affect more than 46 million people worldwide,” wrote Laura D. Baker, Ph.D., of Wake Forest University S chool of Medicine and colleagues. Cocoa extract is rich in compounds called flavanols, and previous small studies suggest that...
Source: Psychiatr News - September 16, 2022 Category: Psychiatry Tags: Alzheimer ' s & Dementia cardiovacsular disease cocoa extract cognitive decline COSMOS-Mind multivitamin Source Type: research

Therapeutic effect of antithrombotic drug combinations in patients with atrial fibrillation undergoing percutaneous coronary intervention for coronary heart disease: a meta-analysis
CONCLUSIONS: DAT with NOACs has a higher safety profile against bleeding in patients with atrial fibrillation after PCI. DAT with VKAs was similar to TAT in terms of antithrombotic effect and incidence of bleeding.PMID:36628223 | PMC:PMC9827321
Source: American Journal of Translational Research - January 11, 2023 Category: Research Authors: Huabin He Xifeng Xiao Xiangyang Yuan Jianhai Chen Source Type: research